Status:
COMPLETED
Screening for Pregnancy Related Heart Failure in Nigeria
Lead Sponsor:
Mayo Clinic
Collaborating Sponsors:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
National Center for Advancing Translational Sciences (NCATS)
Conditions:
Cardiomyopathy
Pregnancy Related
Eligibility:
FEMALE
18-49 years
Phase:
NA
Brief Summary
This study will evaluate the effectiveness of an artificial intelligence-enabled ECG (AI-ECG) for cardiomyopathy detection in an obstetric population in Nigeria.
Eligibility Criteria
Inclusion
- Currently pregnant or within 12 months postpartum
- Willing and able to provide informed consent
Exclusion
- Complex congenital heart disease (single ventricle physiology or significant shunts with cardiac structural changes)
- Significant conduction abnormalities (ventricular pacing on recorded ECG, pacemaker dependence, or severely abnormal/bizarre QRS morphology on ECG tracings)
- Unable or unwilling to provide consent
Key Trial Info
Start Date :
August 15 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 15 2024
Estimated Enrollment :
1232 Patients enrolled
Trial Details
Trial ID
NCT05438576
Start Date
August 15 2022
End Date
May 15 2024
Last Update
May 16 2025
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Rasheed Shekoni Specialist Hospital
Dutse, Jigawa State, Nigeria
2
University of Ilorin Teaching Hospital
Ilorin, Kwara State, Nigeria
3
Olabisi Onabanjo University Teaching Hospital
Sagamu, Ogun State, Nigeria
4
University College Hospital
Ibadan, Oyo State, Nigeria